Medochemie, a prominent Cypriot pharmaceutical exporter, celebrated its 50th anniversary in 2026, reflecting on a remarkable journey from a local start-up in Limassol to a global player in the industry.
Photo: cyprus-mail.com
Cypriot pharmaceutical: From Humble Beginnings to Global Recognition
The company was founded in 1976, during a challenging period as Cyprus was rebuilding after the events of 1974. Young physician Dr Andreas Pittas decided to pursue an unconventional path by establishing a pharmaceutical company in a country with limited industrial opportunities.
Photo: cyprus-mail.com
Dr Pittas’s vision was inspired by his medical studies in Austria, where he developed a profound interest in pharmacology and the potential of pharmaceuticals to enhance lives. Upon returning to Cyprus, he faced scepticism regarding the viability of a Cypriot pharmaceutical exporter, but he remained steadfast in his belief that a credible pharmaceutical industry could emerge from Cyprus.
Building a Foundation on Quality and Innovation
The initial years were marked by significant challenges, including the need to secure resources, technical expertise, and manufacturing capabilities. Yet, quality was always the cornerstone of Medochemie’s identity. The company adhered strictly to European standards, gradually establishing a reputation that would facilitate its expansion into international markets.
Through early partnerships abroad, Medochemie laid the groundwork for a robust export strategy. Today, it stands as the largest pharmaceutical company in Cyprus, recognised as an ambassador of Cypriot pharmaceutical manufacturing worldwide.
Modern Operations and Global Reach
Medochemie operates 15 state-of-the-art manufacturing facilities compliant with strict EU Good Manufacturing Practice (GMP) standards, with nine located in Cyprus, one in the Netherlands, and five in Vietnam. The company maintains a presence in 19 countries and exports its products to 120 markets globally.
As the leading pharmaceutical exporter in Cyprus, Medochemie plays a significant role in the country’s industrial export performance, showcasing Cypriot scientific and manufacturing expertise through each product.
Commitment to Research and Community Engagement
With over 2,000 employees worldwide, Medochemie’s progress is defined not just by financial success but also by its commitment to research, innovation, and the development of human capital. The company has consistently emphasised that business success is most valuable when accompanied by meaningful contributions to society.
Medochemie’s corporate social responsibility programme actively supports education, environmental protection, healthcare, scientific research, and the wellbeing of local communities. Over the years, the company has engaged in various social, cultural, and sporting initiatives, reinforcing its connection to Cypriot society.
Acknowledgements and Future Aspirations
Throughout its history, Medochemie has garnered numerous accolades, including 15 Industrial Export Awards and the prestigious European distinction Ruban d’Honneur, recognising it among Europe’s leading export businesses. These achievements reflect a long-term strategy focused on consistency, expertise, and sustained international development.
“Fifty years later, I feel deeply grateful, not only for what we have achieved but above all for the people who have shared this journey with us. Medochemie is first and foremost its people,” stated Dr Andreas Pittas, the founder and executive chairman. He emphasised the importance of the collective effort and dedication of those who have contributed to the company’s journey.
Continuing the Legacy
As Medochemie looks ahead, it remains committed to investing in research, emerging technologies, and sustainable development while expanding its international footprint. The principles established by Dr Pittas in 1976 continue to shape the company’s evolution, ensuring that it remains a key player in the global pharmaceutical industry.
“Fifty years after its establishment, Medochemie continues to write its own chapter in the history of Cypriot entrepreneurship and the global pharmaceutical industry,” the company stated, underscoring its enduring commitment to quality and innovation.
